The Pathogenic Role of Long Non-coding RNA H19 in Atherosclerosis via the miR-146a-5p/ANGPTL4 Pathway

Shi-Feng Huang1, Guifang Zhao1, Xiao-Fei Peng2

  • 1Qingyuan People's Hospital, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan, China.

Insights

The long non-coding RNA H19 promotes atherosclerosis by increasing lipid accumulation in macrophages. Targeting H19 may offer a new therapeutic strategy for treating cardiovascular disease.

Area of Science:

  • Molecular Biology
  • Cardiovascular Research
  • RNA Biology

Background:

  • Aberrant expression of long non-coding RNA (lncRNA) H19 is implicated in cardiovascular disease.
  • The specific role of lncRNA H19 in atherosclerosis remains largely unknown.
  • Understanding lncRNA H19's function is crucial for developing novel therapeutic strategies.

Purpose of the Study:

  • To investigate the impact of lncRNA H19 on atherogenesis.
  • To elucidate the underlying molecular mechanisms by which lncRNA H19 influences atherosclerosis.
  • To explore the potential of targeting lncRNA H19 as a therapeutic intervention.

Main Methods:

  • Analysis of lncRNA H19 expression in mouse models of atherosclerosis and human cell lines.
  • In vivo studies using adeno-associated virus (AAV)-mediated gene transfer in apoE knockout mice.
  • Assessment of atherosclerotic plaque area, lipid accumulation, and molecular markers (miR-146a-5p, ANGPTL4).

Main Results:

  • lncRNA H19 expression was significantly elevated in atherosclerotic conditions.
  • Overexpression of lncRNA H19 exacerbated atherosclerosis and promoted lipid accumulation in macrophages.
  • lncRNA H19 upregulated ANGPTL4 by inhibiting miR-146a-5p, thereby promoting lipid accumulation.

Conclusions:

  • lncRNA H19 plays a critical role in promoting lipid accumulation and aggravating atherosclerosis progression.
  • The miR-146a-5p/ANGPTL4 pathway is a key mechanism through which lncRNA H19 exerts its effects.
  • Targeting lncRNA H19 presents a promising therapeutic avenue for atherosclerotic diseases.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
164
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.2K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
476
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
79
Inflammation01:38

Inflammation

Overview
56.1K